Prolastin c 1,000 MG/20 ML VLS
Ended Awarded
- Contract number
- SPE2DB25FX7Y0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,860
Award facts
- Contract value 100% obligated
- $15,860.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $15,860.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on September 4, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which establishes the terms and pricing for a comprehensive range of pharmaceutical products supporting the medical supply needs of military health facilities worldwide.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, providing branded and generic prescription drugs, biologics, and medical consumables directly to Department of Defense healthcare sites. The company has demonstrated consistent success in securing delivery orders from the DLA for an extensive portfolio of pharmaceutical items spanning contraceptive devices, oncology treatments, vaccines, auto-injectors, and specialty medications. This particular delivery order for Prolastin C, a protease inhibitor therapy, represents one of many firm fixed-price orders issued under the company's overarching IDC agreement to fulfill ongoing medication requirements across military medical facilities.
Quick answers
Who was awarded contract SPE2DB25FX7Y0?
SPE2DB25FX7Y0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 4, 2025.
How much is contract SPE2DB25FX7Y0 worth?
The government has obligated $15,860 on SPE2DB25FX7Y0.
Is contract SPE2DB25FX7Y0 an order under another contract?
Yes. SPE2DB25FX7Y0 is a delivery order under SPE2DB20D9354, an indefinite delivery contract.
Was contract SPE2DB25FX7Y0 competed?
The extent of competition for SPE2DB25FX7Y0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award